Effects of long-term atorvastatin treatment on cardiac aging

Han,Lei; Li,Minggao; Liu,Xin

doi:10.3892/etm.2013.1208

Effects of long-term atorvastatin treatment on cardiac aging

Authors:
- Lei Han
- Minggao Li
- Xin Liu
View Affiliations

Affiliations: Aerospace and Diving Medical Center, Navy General Hospital of Chinese PLA, Beijing 100037, P.R. China
Published online on: July 5, 2013 https://doi.org/10.3892/etm.2013.1208
Pages: 721-726

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A number of studies have reported that atorvastatin (AVT) may have an important role in the delay of cardiac aging. However, the mechanism by which AVT affects cardiac aging has not been established. In this study, a series of experiments were performed to investigate the effects of AVT treatment on the cardiovascular system and the associated mechanism. Wistar rats were administered AVT or saline for 4 months. Age-related changes in the hearts were measured at the end of the experiment. The results showed that compared with young rats, the aged rats had significant changes indicative of myocardial aging, including increased blood lipid 1evelss, increased body weight, cardiac hypertrophy, larger myocardial cells, irregular muscle fibers, fewer deeply stained nuclei, smaller intercellular spaces, a larger number of apoptotic cells and increased levels of lipofuscin in myocardial tissue. However, long‑term AVT treatment was able to significantly delay or even reverse these aging‑related changes. In addition, these effects showed a certain dose-dependence. In general, long-term AVT treatment reduces blood lipids, inhibits cardiac hypertrophy, suppresses cardiomyocyte apoptosis and lowers the level of oxidative stress to protect the heart from aging.

View Figures

View References

1	Marchand WR, Lee JN, Suchy Y, et al: Age-related changes of the functional architecture of the cortico-basal ganglia circuitry during motor task execution. Neuroimage. 55:194–203. 2011. View Article : Google Scholar : PubMed/NCBI
2	Goldsmith TC: Mammal aging: Active and passive mechanisms and their medical implications. Biosci Hypotheses. 2:59–64. 2009. View Article : Google Scholar
3	Alichniewicz KK, Brunner F, Klünemann HH and Greenlee MW: Structural and functional neural correlates of visuospatial information processing in normal aging and amnestic mild cognitive impairment. Neurobiol Aging. 33:2782–2797. 2012. View Article : Google Scholar : PubMed/NCBI
4	Fowler MR, Naz JR, Graham MD, Orchard CH and Harrison SM: Age and hypertrophy alter the contribution of sarcoplasmic reticulum and Na⁺/Ca²⁺ exchange to Ca²⁺ removal in rat left ventricular myocytes. J Mol Cell Cardiol. 42:582–589. 2007. View Article : Google Scholar : PubMed/NCBI
5	Steppan J, Tran H, Benjo AM, et al: Alagebrium in combination with exercise ameliorates age-associated ventricular and vascular stiffness. Exp Gerontol. 47:565–572. 2012. View Article : Google Scholar : PubMed/NCBI
6	Hung CL, Wu YJ, Liu CC, et al: Age-related ventricular remodeling is an independent risk for heart failure symptoms in subjects with preserved systolic function. Int J Gerontol. 5:17–24. 2011. View Article : Google Scholar
7	Fraysse B, Weinberger F, Bardswell SC, et al: Increased myofilament Ca²⁺ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice. J Mol Cell Cardiol. 52:1299–1307. 2012.
8	Chatterjee K: Pathophysiology of systolic and diastolic heart failure. Med Clin North Am. 96:891–899. 2012. View Article : Google Scholar : PubMed/NCBI
9	Strait JB and Lakatta EG: Cardiac aging: From humans to molecules. Muscle 2-Volume Set: Fundamental Biology and Mechanisms of Disease. Hill JA and Olson EN: 1st edition. Academic Press; Waltham, MA: pp. 639–659. 2012, View Article : Google Scholar
10	Boyle AJ, Shih H, Hwang J, et al: Cardiomyopathy of aging in the mammalian heart is characterized by myocardial hypertrophy, fibrosis and a predisposition towards cardiomyocyte apoptosis and autophagy. Exp Gerontol. 46:549–559. 2011. View Article : Google Scholar
11	Gonzalez-Aparicio R, Flores JA, Tasset I, Tunez I and Fernandez-Espejo E: Mice lacking the peroxisome proliferator-activated receptor alpha gene present reduced number of dopamine neurons in the substantia nigra without altering motor behavior or dopamine neuron decline over life. Neuroscience. 186:161–169. 2011. View Article : Google Scholar
12	Wang XJ, Zhang S, Yan ZQ, et al: Impaired CD200-CD200R-mediated microglia silencing enhances midbrain dopaminergic neurodegeneration: roles of aging, superoxide, NADPH oxidase, and p38 MAPK. Free Radic Biol Med. 50:1094–1106. 2011. View Article : Google Scholar
13	Pisciotta L, Sallo R, Rabacchi C, Wunsch A, Calandra S and Bertolini S: Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia. Nutr Metab Cardiovasc Dis. 22:831–835. 2012. View Article : Google Scholar : PubMed/NCBI
14	Owens CD: Statins and other agents for vascular inflammation. J Vasc Surg. 56:1799–1806. 2012. View Article : Google Scholar : PubMed/NCBI
15	Obregón O, Gestne A, Lares M, et al: Efectos tempranos de las estatinas: inflamación y oxidación. Clin Invest Arterioscl. 23:269–274. 2011.(In Spanish).
16	Marrone G, Russo L, Rosado E, et al: The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. J Hepatol. 58:98–103. 2012. View Article : Google Scholar : PubMed/NCBI
17	Yokomizo A, Shiota M, Kashiwagi E, et al: Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells. Prostate. 71:298–304. 2011. View Article : Google Scholar : PubMed/NCBI
18	Shin SK, Lee YK, Jo YI and Chang TI: The effects of statins unrelated to cholesterol level on clinical outcome of continuous ambulatory peritoneal dialysis patients. Kidney Research and Clinical Practice. 31:A732012. View Article : Google Scholar
19	Choi EY, Chang W, Lim S, et al: Rosuvastatin inhibits norepinephrine-induced cardiac hypertrophy via suppression of Gh. Eur J Pharmacol. 627:56–62. 2010. View Article : Google Scholar : PubMed/NCBI
20	Sverdrup FM, Yates MP, Vickery LE, et al: Protein geranylgeranylation controls collagenase expression in osteoarthritic cartilage. Osteoarthritis Cartilage. 18:948–955. 2010. View Article : Google Scholar
21	Murrow JR, Sher S, Ali S, et al: The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin. J Clin Lipidol. 6:42–49. 2012. View Article : Google Scholar : PubMed/NCBI
22	Chuang YH, Chuang WL, Huang SP, Liu CK and Huang CH: Atorvastatin ameliorates tissue damage of obstructed ureter in rats. Life Sci. 89:795–805. 2011. View Article : Google Scholar : PubMed/NCBI
23	Yang P, Li Y, Li JJ, Qin L and Li XY: Up-regulating PPAR-gamma expression and NO concentration, and down-regulating PAI-1 concentration in a rabbit atherosclerotic model: the possible antiatherogenic and antithrombotic effects of atorvastatin. Int J Cardiol. 139:213–217. 2010. View Article : Google Scholar : PubMed/NCBI
24	Garjani A, Andalib S, Biabani S, Soraya H, Doustar Y, Garjani A and Maleki-Dizaji N: Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat. Eur J Pharmacol. 666:135–141. 2011. View Article : Google Scholar : PubMed/NCBI
25	Koh KK, Quon MJ, Han SH, et al: Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. Int J Cardiol. 146:319–325. 2011. View Article : Google Scholar : PubMed/NCBI
26	Han L, Li M, Liu Y, Han C and Ye P: Atorvastatin may delay cardiac aging by upregulating peroxisome proliferator-activated receptors in rats. Pharmacology. 89:74–82. 2012. View Article : Google Scholar : PubMed/NCBI
27	Kobayashi M, Chisaki I, Narumi K, et al: Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins. Life Sci. 82:969–975. 2008. View Article : Google Scholar : PubMed/NCBI
28	Doyon M, Hale TM, Huot-Marchand JE, Wu R, de Champlain J and deBlois D: Does atorvastatin induce aortic smooth muscle cell apoptosis in vivo? Vascular Pharmacol. 54:5–12. 2011. View Article : Google Scholar : PubMed/NCBI
29	Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubota N, Saito T, Masuda Y, Kadowaki T and Komuro I: Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation. 105:1240–1246. 2002. View Article : Google Scholar
30	Hsu S, Nagayama T, Koitabashi N, et al: Phosphodiesterase 5 inhibition blocks-pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway. Cardiovasc Res. 81:301–309. 2009. View Article : Google Scholar
31	Bao XM, Wu CF and Lu GP: Atorvastatin inhibits homocysteine-induced oxidative stress and apoptosis in endothelial progenitor cells involving Nox4 and p38MAPK. Atherosclerosis. 210:114–121. 2010. View Article : Google Scholar : PubMed/NCBI
32	Yu X and Li G: Effects of resveratrol on longevity, cognitive ability and aging-related histological markers in the annual fish Nothobranchius guentheri. Exp Gerontol. 47:940–949. 2012. View Article : Google Scholar : PubMed/NCBI
33	Höhn A, Sittig A, Jung T, Grimm S and Grune T: Lipofuscin is formed independently of macroautophagy and lysosomal activity in stress-induced prematurely senescent human fibroblasts. Free Radic Biol Med. 53:1760–1769. 2012.PubMed/NCBI